Opendata, web and dolomites

UNITY SIGNED

Unified, holistic medical data collection and analysis platform

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "UNITY" data sheet

The following table provides information about the project.

Coordinator
RAYLYTIC GMBH 

Organization address
address: SCHILLERSTR. 5
city: LEIPZIG
postcode: 4109
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://www.raylytic.com/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RAYLYTIC GMBH DE (LEIPZIG) coordinator 50˙000.00

Map

 Project objective

Due to the new EU Medical Device Regulations, the medical device industry needs to continuously obtain more and more accurate clinical data. However, due to limited resources, high costs and long clinical trial durations this data may not be obtained, resulting in (temporary) removal of proven medical devices from the EU market, while new devices may only be available in the EU with significant delay. Hence, the industry is desperately searching for solutions to accurately document clinical evidence of existing and new treatment options in a time and cost-efficient way. We are Raylytic, a German SME from Leipzig, specialised in clinical trials and radiographic image analysis. Since 3 years we have identified the described new business opportunity and started developing UNITY: a unique medical data collection and analysis platform that integrates traditional data collection (clinical data, patient outcome, lab data) with medical image analysis. Thanks to our advances in computer vision and medical image analysis technology, UNITY will be the next state-of-the-art solution, tapping into the clinical diagnostics, imaging software and pharmaceutical trials markets. The impact of UNITY for our clinical trial clients is a cost reduction of up to 40% for the execution of clinical trials. We have identified a favourable regulatory and reimbursement pathway. With the described project we intend to prepare UNITY for FDA and CE market clearance and subsequent successful market launch by 2022. After the project and upon regulatory approval, we intend to directly follow up and sell UNITY to hospitals as a hardware-vendor independent computer-aided diagnosis solution, as they will be using the platform already in clinical trials. Through this project (estimated ROI of 14.2), the company aims to boost its competitiveness, by increasing its revenues to €3 Million and its team to 25 employees by the first year of commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UNITY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UNITY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

NAAS (2019)

NaaS - Newsroom as a service

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More